photo-teva-2
Photo: Courtesy of Teva
22 June 2015Americas

Teva’s Copaxone patent invalidated for second time

A US appeals court has for the second time invalidated a patent covering pharmaceutical company Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 January 2015   The US Supreme Court has vacated an appeals court judgment that invalidated a patent covering Teva’s blockbuster drug Copaxone (glatiramer acetate).

More on this story

Americas
20 January 2015   The US Supreme Court has vacated an appeals court judgment that invalidated a patent covering Teva’s blockbuster drug Copaxone (glatiramer acetate).

More on this story

Americas
20 January 2015   The US Supreme Court has vacated an appeals court judgment that invalidated a patent covering Teva’s blockbuster drug Copaxone (glatiramer acetate).